{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Rhythm Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"RYTM"},"Address":{"label":"Address","value":"222 BERKELEY STREET,12TH FLOOR, BOSTON, Massachusetts, 02116, United States"},"Phone":{"label":"Phone","value":"+1 857 264-4280"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies."},"CompanyUrl":{"label":"Company Url","value":"http://www.rhythmtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alastair Garfield","title":"Chief Scientific Officer"},{"name":"Dana S. Washburn","title":"Senior Vice President-Clinical Development"},{"name":"David P. Meeker","title":"Chairman, President & Chief Executive Officer"},{"name":"Joseph Shulman","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}